ELTROXIN 300 MCG — DIN 02213230
LEVOTHYROXINE SODIUM : 300 MCG · ASPEN PHARMACARE CANADA INC. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ELTROXIN?
ELTROXIN 300 MCG contains LEVOTHYROXINE SODIUM : 300 MCG. It is listed in the Health Canada Drug Product Database under DIN 02213230, held by ASPEN PHARMACARE CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Sep-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ELTROXIN used for?
Replacement therapy for hypothyroidism of any etiology (except transient subacute thyroiditis); TSH suppressant for euthyroid goiters and thyroid cancer management.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Levothyroxine Sodium cost around the world?
Levothyroxine Sodium is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); United Kingdom publishes a hospital. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 12 | 305 | USD███.██ |
| Greece | producer price (ex-factory) | 69 | 69 | EUR███.██ |
| Australia | ex-manufacturer | 9 | 37 | AUD███.██ |
| United Kingdom | hospital | 9 | 9 | GBP███.██ |
420 pack listings across 99 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every Levothyroxine Sodium pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Levothyroxine Sodium in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Levothyroxine Sodium, across 109 DINs, of which 33 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 12 | 12 | APO-LEVOTHYROXINE | Sourceable in Canada |
| BGP PHARMA ULC | 12 | 12 | SYNTHROID | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 12 | 4 | ELTROXIN | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 4 | 3 | LEVOTHYROXINE SODIUM FOR INJECTION, LEVOTHYROXINE SODIUM INJECTION | Sourceable in Canada |
| AVIR PHARMA INC. | 2 | 2 | LEVOTHYROXINE SODIUM FOR INJECTION | Sourceable in Canada |
| PHARMASCIENCE INC | 16 | 0 | LEVO-T 100MCG - TAB, LEVO-T 125MCG - TAB, LEVO-T 150MCG - TAB, LEVO-T 200MCG - TAB, LEVO-T 25MCG - TAB, +11 more | No marketed DIN |
| BOOTS PHARMACEUTICALS LTD. | 12 | 0 | SYNTHROID LIQ INJ 500MCG/VIAL USP, SYNTHROID TAB 100MCG USP, SYNTHROID TAB 112MCG USP, SYNTHROID TAB 125MCG USP, SYNTHROID TAB 150MCG USP, +7 more | No marketed DIN |
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 12 | 0 | EUTHYROX | No marketed DIN |
| IBSA INSTITUT BIOCHIMIQUE SA | 12 | 0 | TIROCAP | No marketed DIN |
| TECHNILAB PHARMA INC. | 10 | 0 | LEVOTEC 100MCG TABLETS USP, LEVOTEC 112MCG TABLETS USP, LEVOTEC 125MCG TABLETS USP, LEVOTEC 150MCG TABLETS USP, LEVOTEC 175MCG TABLETS USP, +5 more | No marketed DIN |
| GLAXO CANADA INC | 5 | 0 | ELTROXIN 150 TAB, ELTROXIN TAB 100MCG, ELTROXIN TAB 200MCG, ELTROXIN TAB 300MCG, ELTROXIN TAB 50MCG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MCG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100 and 500 tablets. |
| Storage | Not explicitly detailed in the provided text snippet (section 11 is in TOC but text ends at section 7.1.3). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Levothyroxine Sodium |
|---|---|
| ATC code | H03AA01 |
| AHFS class | 68:36.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02213230 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2213230 |
| Brand name | ELTROXIN |
| Generic / active ingredient | LEVOTHYROXINE SODIUM : 300 MCG |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | H03AA01 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H03AA |
| Current status | CANCELLED POST MARKET |
| Status date | 17-Sep-2018 |
| Original market date | 1998-02-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: ~1.7 mcg/kg/day once daily. Adjust by 12.5-25 mcg increments every 6-8 weeks until TSH is normalized. Administer on an empty stomach.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; untreated subclinical or overt thyrotoxicosis; acute myocardial infarction, myocarditis, or pancarditis; uncorrected adrenal insufficiency.
Warnings and precautions
Not for obesity/weight loss. Narrow therapeutic index. Exercise caution in patients with cardiovascular disorders (angina, CAD) and the elderly. May decrease bone mineral density.
Is Levothyroxine Sodium in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 24 Apr 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
33 of 109 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LEVOTHYROXINE | 137 MCG | TABLET | APOTEX INC | MARKETED | 02550776 |
| APO-LEVOTHYROXINE | 75 MCG | TABLET | APOTEX INC | MARKETED | 02550725 |
| APO-LEVOTHYROXINE | 112 MCG | TABLET | APOTEX INC | MARKETED | 02550741 |
| APO-LEVOTHYROXINE | 125 MCG | TABLET | APOTEX INC | MARKETED | 02550768 |
| APO-LEVOTHYROXINE | 300 MCG | TABLET | APOTEX INC | MARKETED | 02534703 |
| APO-LEVOTHYROXINE | 100 MCG | TABLET | APOTEX INC | MARKETED | 02534681 |
| APO-LEVOTHYROXINE | 50 MCG | TABLET | APOTEX INC | MARKETED | 02550717 |
| APO-LEVOTHYROXINE | 88 MCG | TABLET | APOTEX INC | MARKETED | 02550733 |
| APO-LEVOTHYROXINE | 25 MCG | TABLET | APOTEX INC | MARKETED | 02550709 |
| APO-LEVOTHYROXINE | 150 MCG | TABLET | APOTEX INC | MARKETED | 02550784 |
2 · Same class — other molecules in ATC H03AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levothyroxine Sodium | APO-LEVOTHYROXINE · ELTROXIN · ELTROXIN 150 TAB · ELTROXIN TAB 100MCG · +46 more | 109 | 33 | Yes |
| Liothyronine Sodium | AURO-LIOTHYRONINE · CYTOMEL · TEVA-LIOTHYRONINE | 6 | 6 | Yes |
| Thyroid Gland Preparations | ERFA THYROID | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ELTROXIN called?
The same molecule, Levothyroxine Sodium, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Levothyroxine | Latin | Australia |
| Eutroxsig | Latin | Australia |
| Levothox | Latin | Australia |
| Levothyroxine Lup | Latin | Australia |
| Levothyroxine Sandoz | Latin | Australia |
| LEVOXINE | Latin | Australia |
| Oroxine | Latin | Australia |
| Thyrox | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.